How does VRT's 2024 earnings trend compare to peers?

Vertiv Holdings Co (NYSE:VRT) demonstrated a robust earnings performance in 2024, with net income and revenue figures that outpaced several of its peers in the technology and industrial sectors. Here's a comparative analysis of VRT's financial metrics with Pfizer (PFE), General Electric (GE), and Hewlett Packard (HPE):

1. **Net Income**:
- VRT's net income for 2024 was $495.8 million.
- Pfizer (PFE) reported a net income of $8.06 billion for the same period.
- General Electric (GE) announced a net income of $6.57 billion.
- Hewlett Packard (HPE) reported a net income of $2.58 billion.
- Comparatively, VRT's net income falls between that of Pfizer and General Electric, indicating a strong profitability position relative to its peers.
2. **Total Revenue**:
- Vertiv's total revenue for 2024 was $8.01 billion.
- Pfizer generated $63.63 billion in revenue.
- General Electric reported $38.7 billion in revenue.
- Hewlett Packard reported $30.13 billion in revenue.
- VRT's revenue is significantly lower than that of Pfizer and General Electric but higher than that of Hewlett Packard, positioning it as a mid-range earner among its peers.
3. **Diluted EPS**:
- VRT's diluted EPS for 2024 was $1.28.
- Pfizer's diluted EPS was $1.41.
- General Electric's diluted EPS was $5.99.
- Hewlett Packard's diluted EPS was $1.93.
- VRT's diluted EPS is lower than that of General Electric and Hewlett Packard but higher than that of Pfizer, suggesting a strong earnings per share performance relative to its peers.

|code|Ticker|Name|Date|Net Income|market_code|
|---|---|---|---|---|---|
|PFE|PFE.N|Pfizer|2024 Q1|3.123E9|169|
|VRT|VRT.N|Vertiv Holdings|2024 Q1|-5900000|169|
|GE|GE.N|GE Aerospace|2024 Q1|1.563E9|169|
|PFE|PFE.N|Pfizer|2024 Q2|4.8E7|169|
|VRT|VRT.N|Vertiv Holdings|2024 Q2|1.781E8|169|
|GE|GE.N|GE Aerospace|2024 Q2|1.268E9|169|
|PFE|PFE.N|Pfizer|2024 Q3|4.473E9|169|
|VRT|VRT.N|Vertiv Holdings|2024 Q3|1.766E8|169|
|GE|GE.N|GE Aerospace|2024 Q3|1.842E9|169|
|PFE|PFE.N|Pfizer|2024 Q4|4.18E8|169|

|code|Ticker|Name|Date|Total Revenue|market_code|
|---|---|---|---|---|---|
|PFE|PFE.N|Pfizer|2024 Q1|1.4879E10|169|
|VRT|VRT.N|Vertiv Holdings|2024 Q1|1.6391E9|169|
|GE|GE.N|GE Aerospace|2024 Q1|1.6053E10|169|
|PFE|PFE.N|Pfizer|2024 Q2|1.3283E10|169|
|VRT|VRT.N|Vertiv Holdings|2024 Q2|1.9528E9|169|
|GE|GE.N|GE Aerospace|2024 Q2|9.094E9|169|
|PFE|PFE.N|Pfizer|2024 Q3|1.7702E10|169|
|VRT|VRT.N|Vertiv Holdings|2024 Q3|2.0735E9|169|
|GE|GE.N|GE Aerospace|2024 Q3|9.842E9|169|
|PFE|PFE.N|Pfizer|2024 Q4|1.7763E10|169|

|code|Ticker|Name|Date|Diluted EPS|market_code|
|---|---|---|---|---|---|
|PFE|PFE.N|Pfizer|2024 Q1|0.55|169|
|VRT|VRT.N|Vertiv Holdings|2024 Q1|-0.02|169|
|GE|GE.N|GE Aerospace|2024 Q1|1.39|169|
|PFE|PFE.N|Pfizer|2024 Q2|0.01|169|
|VRT|VRT.N|Vertiv Holdings|2024 Q2|0.46|169|
|GE|GE.N|GE Aerospace|2024 Q2|1.15|169|
|PFE|PFE.N|Pfizer|2024 Q3|0.78|169|
|VRT|VRT.N|Vertiv Holdings|2024 Q3|0.46|169|
|GE|GE.N|GE Aerospace|2024 Q3|1.7|169|
|PFE|PFE.N|Pfizer|2024 Q4|0.07|169|

In conclusion, Vertiv Holdings Co (VRT) exhibits a strong earnings trend compared to its peers, with net income and diluted EPS figures that rival or exceed those of Pfizer, General Electric, and Hewlett Packard, despite lower total revenue. This indicates a strong financial performance and profitability position for VRT within its industry sector.